Skip to main content

Table 3 Relationships between Trail Making Test A performance and ACE-I vs. ARB use over time (n = 1601)

From: The use of angiotensin-converting enzyme inhibitors vs. angiotensin receptor blockers and cognitive decline in Alzheimer’s disease: the importance of blood-brain barrier penetration and APOE ε4 carrier status

 

Overall

APOE ε4 non-carriers

APOE ε4 carriers

B [95% CI]

z

p value

B [95% CI]

z

p value

B [95% CI]

z

p value

ARBs vs. ACE-Is

2.023 [0.492, 3.553]

2.59

0.0096

4.066 [1.816, 6.317]

3.54

0.0004

1.458 [− 0.365, 3.282]

1.57

0.1171

C-ARBs vs. NC-ACE-Is

3.349 [0.766. 5.933]

2.54

0.0110

6.086 [2.431, 9.741]

3.26

0.0011

2.054 [− 1.123, 5.230]

1.35

0.1785

C-ACE-Is vs. NC-ACE-Is

0.985 [− 0.121, 3.184]

0.88

0.3798

1.604 [− 1.061, 4.810]

0.98

0.3267

0.771 [− 1.892, 3.434]

0.57

0.5703

NC-ARBs vs. NC-ACE-Is

2.316 [− 0.176, 4.810]

1.82

0.0685

4.480 [0.844, 8.116]

2.42

0.0157

2.049 [− 0.936, 5.034]

1.27

0.2051

C-ARBs vs. NC-ARBs

1.033 [− 1.228, 3.293]

0.90

0.3705

1.606 [− 1.510, 4.722]

1.01

0.3125

0.005 [− 2.598, 2.608]

0.01

0.9971

C-ARBs vs. C-ACE-Is

2.364 [0.308, 4.420]

2.25

0.0242

4.482 [1.620, 7.343]

3.07

0.0022

1.283 [− 1.172, 3.737]

1.02

0.3058

  1. Three-way APOE × ARB vs. ACE-I × Time interaction: B = 2.608 [− 0.300, 5.516] s, z = 1.76, p = 0.0788
  2. C-ARB: BBB-crossing ARB; C-ACE-I: BBB-crossing ACE-I; NC-ARB: Non-BBB-crossing ARB; NC-ACE-I: Non-BBB-crossing ACE-I